In a phase 2b trial, efruxifermin significantly improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis, with the 50 mg dose showing the greatest benefit.
A new analysis of national mortality data highlights increases in alcohol-related deaths in the United States from 1999 to 2020, underscoring the urgency of addressing this growing public health crisis.
...
In a cohort study, researchers observed a significant decrease in incident reinfection among patients with Hepatitis C who received increased follow-up after achieving sustained virologic response.
Individuals with acute hepatic porphyria often experience acute attacks and chronic symptoms which greatly diminish their quality of life. Researchers examined the efficacy of givosiran in reducing these...
The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
The researchers set out to determine the mortality risk and complications associated with direct-acting antiviral treatment in patients with chronic hepatitis C.
